← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
51	51 Abeona Therapeutics ABEO $249M	37	-8	-18%	$15.8M
52	52 Pluri PLUR $11.7M	37	+1	+3%	$3.74M
53	53 Opus Genetics IRD $341M	35	-1	-3%	$10.1M
54	54 Neurogene NGNE $444M	34	-1	-3%	$102M
55	55 CareDx CDNA $3.35B	27	+2	+8%	$27.8M
56	56 Imunon IMNN $5.84M	26	+2	+8%	$4.98M
57	57 ProQR Therapeutics PRQR $207M	26	-3	-10%	$44.3M
58	58 DELISTED Carisma Therapeutics CARM	25	+2	+9%	$8.34M
59	HTGM 59 DELISTED HTG Molecular Diagnostics, Inc. Common Stock HTGM	23	+2	+10%	$9.07M
60	ONCS 60 DELISTED OncoSec Medical Incorporated ONCS	23	+3	+15%	$2.26M
61	61 DELISTED BRAINSTORM CELL THERAPUTC BCLI	22	-6	-21%	$3.93M
62	62 Capricor Therapeutics CAPR $383M	22	+3	+16%	$2.9M
63	63 DELISTED BioLife Solutions BLFS	17	+1	+6%	$609K
64	64 Ocugen OCGN $285M	16	-3	-16%	$8.77M
65	65 Cartesian Therapeutics RNAC $192M	16	+16	–	$105M
66	66 Mesoblast MESO $1.79B	15	-2	-12%	$10.3M
67	67 Enlivex Ltd ENLV $4.29M	13	+5	+63%	$2.05M
68	PTE 68 DELISTED PolarityTE, Inc. Common Stock PTE	10	-1	-9%	$536K
69	69 Eterna Therapeutics ERNA $2.46M	7	+1	+17%	$3.31M
70	CYAD 70 DELISTED Celyad Oncology SA American Depositary Shares CYAD	6	-2	-25%	$10.6M
71	71 ARK Genomic Revolution ETF ARKG $2.05B	4	-2	-33%	$897K
72	72 Benitec Biopharma BNTC $289M	3	0	0%	$441K
73	73 Qiagen QGEN $9.41B	1	-2	-67%	$458
74	74 DELISTED Scorpius Holdings, Inc. SCPX	1	-2	-67%	$1.19M
75	75 Adicet Bio ACET $45.8M	–	–	–	–